The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma
Min Pan, William C. Wright, Rich Chapple, Asif Zubair, Manbir Sandhu, Jake Batchelder, Jonathan Low, Kaley B Blankenship, Yingzhe Wang, Brittney Gordon, Payton Archer, Samuel W. Brady, Sivaraman Natarajan, Matthew J. Posgai, John Schuetz, Darcie Miller, Ravi Kalathur, Siquan Chen, Jon Patrick Connelly, M. Madan Babu, Michael A. Dyer, Shondra M. Pruett-Miller, Burgess B. Freeman III, Taosheng Chen, Lucy A. Godley, Scott Blanchard, Elizabeth Stewart, John Easton, Paul Geeleher
bioRxiv 2021.02.25.432934; doi: https://doi.org/10.1101/2021.02.25.432934